Immune Modulatory DC Vaccine Against Brain Tumor

Prior treatment

• A prior history of gliadel implantation 4 weeks before this study start or antibody based therapies;
• The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection;
• Patients who had previously been treated with cell therapy but were ineffective after physical examination were discussed and confirmed by team experts and were not suitable for re-treatment;

Other illness

• Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs;
• Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products;
• Active infection with fever;
• Infection with bacteria, fungi or viruses, uncontrolled;
• Patients with HIV and those living with active HBV and HCV;
• Important organ failure (heart, liver, kidney, lung);

Other

• Patients with neutropenia (\> 10 days) that are difficult to correct after treatment;
• Pregnant, pregnant and lactating women;
• Anything that researchers believe may increase the risk of subjects or interfere with test results.

• Abilities to understand and the willingness to provide written informed consent. Assent will be obtained when appropriate based on the subjects age;
• Patients are ≥ 6 months and ≤ 80 years old;
• DIPG or GBM patients with existing or measurable tumors in the brain. Patients have received standard care of medication, such as gross total resection with concurrent radio chemotherapy (\~54 - 60 Gy, TMZ);
• Patients with adequate neurological function and epileptic symptoms that are well controlled;
• Observing the condition after surgery or without surgery;
• Karnofsky performance score (KPS) ≥ 60;Life expectancy \>3 months;
• Important organ function is satisfied: Cardiac ultrasound indicates a cardiac ejection fraction ≥50%; and there is no obvious abnormality in the electrocardiogram; blood oxygen saturation ≥90%; creatinine \<2.5 times normal range; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 times normal range; Total bilirubin ≤ 2.0 mg / dl; Hgb (hemoglobin) ≥ 80g / L;
• Peripheral blood absolute lymphocyte count must be above 0.8×10\^9/L;
• Adequate Neurologic Function Defined as: Patients with seizure disorder may be enrolled if seizure disorder is well controlled;
• Patients must be willing to follow the orders of doctors.